MELD Score (Original, Pre-2016, Model for End-Stage Liver Disease)

ورودی‌های بالینی بیمار

حداقل ۰.۰۱ — حداکثر ۴۰ • واحد: mg/dL

حداقل ۱e-۸ — حداکثر ۵۰ • واحد: mg/dL

حداقل ۰.۱ — حداکثر ۲۰

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
meld score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk6–9
  • Moderate Risk10–19
  • High Risk20–29
  • Very High Risk30–39

Clinical Decision Pathway

Clinical Decision Pathway & Next Steps

Hepatology, Alcoholic Hepatitis & GI Bleeding — بیماری‌های کبدی، هپاتیت الکلی و خونریزی گوارشی

Clinical Rationale:

Assess chronic liver failure with Child-Pugh, MELD, and MELD-Na; evaluate alcoholic hepatitis severity with Maddrey and GAHS for steroid indication, and triage upper GI bleeding with Glasgow-Blatchford and AIMS65.

← Previous Step in PathwayPrior step

Child-Pugh Score for Cirrhosis Mortality

امتیاز چایلد-پیو (پیش‌آگهی سیروز)

Review previous tool

Recommended Clinical Next Steps:

  • MELD Na (UNOS/OPTN)

    امتیاز MELD-Na (UNOS/OPTN)

    Why next: Liver transplant allocation priority with sodium
  • Maddrey's Discriminant Function for Alcoholic Hepatitis

    تابع مادری برای هپاتیت الکلی

    Why next: Corticosteroid indication in alcoholic hepatitis
  • Glasgow Alcoholic Hepatitis Score (GAHS)

    امتیاز هپاتیت الکلی گلاسکو (GAHS)

    Why next: Predict survival response to corticosteroid therapy
Direct Clinical Answer

The MELD Score (Original, Pre-2016, Model for End-Stage Liver Disease) calculates assessing gastrointestinal disease severity, endoscopic intervention urgency, and rebleeding risk. Key inputs include creatinine. Scores guide timing emergent endoscopy, initiating high-dose proton pump inhibitor infusions, or obtaining surgical consultation. Routine clinical application promotes standardized evidence-based patient management.

Clinical Guidelines & Evidence

Quantifies end-stage liver disease for transplant planning using the original pre-2016 formula without sodium

Clinical Indication

The MELD Score (Original, Pre-2016, Model for End-Stage Liver Disease) is indicated for bedside clinical practice to support Quantifies end-stage liver disease for transplant planning using the original pre-2016 formula without sodium. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with upper or lower gastrointestinal hemorrhage, acute pancreatitis, acute liver failure, or inflammatory bowel disease. Clinical application is indicated across Endoscopy suites, emergency GI triage, acute medical floors, and hepatology services.

Limitations & Contraindications

Initial hemoglobin values in hyperacute hemorrhage may falsely appear normal prior to complete extravascular-to-intravascular fluid equilibration.

Clinical Pearls & Action Plan

Aggressive intravascular volume resuscitation and blood product support must precede diagnostic or therapeutic endoscopy.

Formula & Variables:

MELD = (0.957 × ln(Cr) + 0.378 × ln(bilirubin) + 1.120 × ln(INR) + 0.643) × 10

Input Parameters

NameTypeRequiredDescription
creatininefloatYesSerum creatinine in mg/dL. If patient on hemodialysis, use 4.0. If <1.0, use 1.0(mg/dL)
bilirubinfloatYesTotal bilirubin in mg/dL. If <1.0, use 1.0(mg/dL)
inrfloatYesInternational Normalized Ratio (INR). If <1.0, use 1.0
dialysisstringYesHas the patient had hemodialysis at least twice in the past week?

Score Interpretation & Guidance

RangeStageDescription
6–9Low RiskMELD ≤9
10–19Moderate RiskMELD 10-19
20–29High RiskMELD 20-29
30–39Very High RiskMELD 30-39
40–40Extremely High RiskMELD ≥40

Evidence-Based References (EBM)

  • Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70. doi: 10.1053/jhep.2001.22172.DOI: 10.1053/jhep.2001.22172
  • Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003 Jan;124(1):91-6. doi: 10.1053/gast.2003.50016.DOI: 10.1053/gast.2003.50016
  • Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000 Apr;31(4):864-71. doi: 10.1053/he.2000.5852.DOI: 10.1053/he.2000.5852

Related calculators